Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More
A wave of blockbuster generic drugs launches, new brand drugs that address unmet needs, and legislation that would bring transparency to...
top of page
Subscriber login:
SUBMIT
Remember me
Search
Aug 28, 2023
CMS Releases List of Drugs for Medicare Price Negotiation
The Centers for Medicare and Medicaid Services (CMS) has released the list of the first 10 drugs to be negotiated under the Inflation...
Jul 31, 2023
Using Technology to Transform Specialty Medication Access and Affordability
We need a streamlined approach where stakeholders can perform all critical tasks — from enrollment and patient consent to prior...
Jul 31, 2023
From Bottlenecks to Breakthroughs: Using Technology to Transform Specialty Medication Access and Affordability
We need a streamlined approach where stakeholders can perform critical tasks — from enrollment and patient consent to prior authorization
Jun 15, 2023
What to Look For in the Pipeline, Misconceptions of Drug Approvals and More with Jeffrey Casberg
Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the...
Mar 27, 2023
PDTs, Biosimilars, Hot Topics at AMCP meeting | AMCP 2023
The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for...
Mar 24, 2023
Jeffrey Casberg on Breakthrough Ophthalmic Drugs that Payers, Pharmacists Should Pay Attention To
Jeffrey Casberg, Senior Director of Pharmacy at IPD Analytics discusses some of the high-impact specialty drugs in various therapeutic...
Mar 23, 2023
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne...
Mar 23, 2023
Beta Thalassemia Requires Specialized Management for Patients, Payors and Pharmacists
Dr. Billings, PharmD, BCGP, and Dr. Mahler, PhD, of IPD Analytics discuss specialized treatment with Beta Thalassemia at AMCP 2023. By...
Feb 14, 2023
Exclusive: Profiling Manufacturers’ Limited and Exclusive Pharmacy Networks for Specialty Drugs
A deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and...
Feb 9, 2023
Drug Pathways, Potential Mechanisms of Resistance in PARP Inhibition
PARPi monotherapy has been a milestone in the management of many BRCA1/2-mutated cancers, offering patients and prescribers the hope of...
Nov 16, 2022
IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic,...
Oct 13, 2022
How to Make Accumulator, Maximizer Programs More Acceptable to Your Patients l AMCP Nexus 2022
Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways...
Aug 22, 2022
High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023
The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already...
Jul 20, 2022
California Initiative Provides $100 Million to Produce Its Own Insulin Biosimilars
The budget allocates half of the money for the development of low-cost interchangeable insulin biosimilars and the other half for...
Jul 15, 2022
Biogen/ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
ICER's expert group unanimously voted against Biogen's Aduhelm and its benefit for Alzheimer's patients. (Biogen) By Noah Higgins-Dunn |...
Jun 21, 2022
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...
May 31, 2022
6 Payor Tactics to Control Drug Spending
Kimberly Grant, PharmD, and Julia Mahler, PharmD, clinical pharmacists with IPD Analytics, state that specialty products are outpacing...
May 31, 2022
Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...
May 29, 2022
New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says
With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...
May 25, 2022
Payer Management Tools and Trends for Biosimilars in the US
As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...
Apr 11, 2022
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...
Mar 31, 2022
Upcoming Generics Provide New Considerations and Opportunities for Savings
In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...
Mar 29, 2022
Jeffery Casberg Previews His Presentations at AMCP 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products...
bottom of page